Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04305145

Title field or adapter rule

{'original_value': 'Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.608812+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:19:00.066997+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Melanoma Stage III", "Melanoma Stage IV", "Skin Cancer Stage III", "Skin Cancer Stage IV", "Drug-Induced Colitis", "Drug Toxicity", "Immune-related Adverse Event"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04305145"

protocolSection.identificationModule.officialTitle

"Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Melanoma Stage III (protocolSection.conditionsModule.conditions)
• Melanoma Stage IV (protocolSection.conditionsModule.conditions)
• Skin Cancer Stage III (protocolSection.conditionsModule.conditions)
• Skin Cancer Stage IV (protocolSection.conditionsModule.conditions)
• Drug-Induced Colitis (protocolSection.conditionsModule.conditions)
• Drug Toxicity (protocolSection.conditionsModule.conditions)
• Immune-related Adverse Event (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Infliximab'], 'description': 'Infusion', 'name': 'Infliximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Corticosteroids'], 'description': 'Infusion', 'name': 'Methylprednisolone', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Corticosteroids'], 'description': 'Orally', 'name': 'Prednisone', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Infliximab (protocolSection.armsInterventionsModule.interventions[].name)
• Methylprednisolone (protocolSection.armsInterventionsModule.interventions[].name)
• Prednisone (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.